Floatz logo

Abi-007

Urinary Bladder Neoplasms

CelgeneSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Urinary Bladder Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB
Nivolumab
Ikena Oncology
Phase 2B

View all 37 →

Same molecule, other indications

Abi-007 is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →